CALIPER健康儿童队列中17项特殊免疫分析与肿瘤标志物在Abbott Alinity i系统的儿科参考区间验证
该研究依据CLSI EP-28A3C指南,在CALIPER健康儿童青少年队列(出生至18岁,n=100)中验证Abbott Alinity i系统17项特殊免疫分析(含肿瘤抗原、自身免疫肽和激素)的儿科参考区间可转移性。以ARCHITECT系统已建立的CALIPER参考区间为参照,仅抗环瓜氨酸肽(anti-CCP)未满足≥90%结果落在参照置信区间内的验证标准,其余16项通过验证。
要点
- 16项特殊免疫分析在Alinity i系统可沿用ARCHITECT的CALIPER儿科参考区间。
- 抗环瓜氨酸肽(anti-CCP)未通过验证,需进一步建立解释性推荐。
- 抗甲状腺球蛋白、抗甲状腺过氧化物酶和癌胚抗原在1岁后无需年龄特异参考区间。
核心结论
- CALIPER队列中16项特殊免疫分析的儿科参考区间可从ARCHITECT系统转移至Alinity i系统。
- 抗环瓜氨酸肽(anti-CCP)未满足≥90%结果落在ARCHITECT参考置信区间内的验证标准。
研究设计与样本
- 依据CLSI EP-28A3C指南,对17项特殊Alinity免疫分析完成精密度、线性和方法学比对实验。
- 纳入健康儿童和青少年(出生至18岁,n=100)血清样本,以ARCHITECT系统已建立的CALIPER参考区间为参照进行验证。
主要发现
- 17项特殊免疫分析中仅抗环瓜氨酸肽(anti-CCP)未达到可接受验证标准(即≥90%结果落在ARCHITECT参考置信区间内)。
- 抗甲状腺球蛋白、抗甲状腺过氧化物酶和癌胚抗原分别有63%、91%和80%的样本等于检测限,1岁后无需年龄特异考虑。
- 相关分析(如性激素结合球蛋白、总前列腺特异抗原和游离前列腺特异抗原)的估计值按性别分开。
关键数值与推荐
- 验证可接受标准为≥90%的结果落在ARCHITECT参考置信区间内。
- 抗甲状腺球蛋白、抗甲状腺过氧化物酶和癌胚抗原分别有63%、91%和80%的样本等于检测限。
临床怎么用
- 儿科临床实验室使用Alinity i系统时,可参考本研究结果沿用16项特殊免疫分析的CALIPER儿科参考区间。
- 抗环瓜氨酸肽(anti-CCP)的儿科参考区间需进一步研究以建立循证解释性推荐。
局限性
- 抗环瓜氨酸肽(anti-CCP)未通过验证,需进一步工作建立循证解释性推荐。
- 需继续评估新检测技术的儿科参考区间可接受性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Clinical laboratory investigation of autoimmune, metabolic, and oncologic disorders in children and adolescents relies on appropriateness of reference intervals (RIs). The Canadian Laboratory Initiative on Pediatric Reference Intervals (CALIPER) previously established comprehensive pediatric RIs for specialized immunoassays on the Abbott ARCHITECT system. Herein, we aim to verify performance on new Alinity i assays by evaluating sera collected from healthy children as per Clinical and Laboratory Standards Institute (CLSI) EP-28A3C guidelines. METHODS: Precision, linearity, and method comparison experiments were completed for 17 specialized Alinity immunoassays, including cancer antigens, autoimmune peptides, and hormones. Sera collected from healthy children and adolescents (birth-18 years, n=100) were evaluated. CLSI-based verification was completed using previously established CALIPER RIs for ARCHITECT assays as the reference. RESULTS: Of 17 specialized immunoassays assays, only anti-cyclic citrullinated peptides (anti-CCP) did not meet acceptable verification criterion (i.e., ≥90% of results within ARCHITECT reference CI). Anti-thyroglobulin, anti-thyroid peroxidase, and carcinoembryonic antigen did not require age-specific consideration beyond one year of age, with 63, 91, and 80% of samples equalling the limit of detection, respectively. Estimates were separated by sex for relevant assays (e.g., sex hormone binding globulin, total and free prostate specific antigen). CONCLUSIONS: Findings support transferability of pediatric RIs on ARCHITECT system to the Alinity system for 16 specialized immunoassays in the CALIPER cohort and will be a useful resource for pediatric clinical laboratories using Alinity assays. Further work is needed to establish evidence-based interpretative recommendations for anti-CCP and continue to evaluate pediatric RI acceptability for newly available assay technologies.
引用
- Bohn MK, Wilson S, Schneider R, et al. Pediatric reference interval verification for 17 specialized immunoassays and cancer markers on the Abbott Alinity i system in the CALIPER cohort of healthy children and adolescents. Clin Chem Lab Med. 2022. PMID: 36117243. doi:10.1515/cclm-2022-0709
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。